
Endocrinologists IDENTIFYING PATIENTS WITH VITAMIN B12 DEFICIENCY



HISTORY

Diagnosed with Type 2 diabeted

Hypercholesterolemia

Hypertensive

Gastroesophageal reflux dise

IMPORTANT SAFETY INFORMATION FOR NASCOBAL® NASAL SPRAY

NASCOBAL[®] is contraindicated in patients with sensitivity to cobalt, vitamin B₁₂, or any component of the medication. Anaphylactic shock and death have been reported with parenteral forms of vitamin B₁₂. Consider administering an intradermal test dose of parenteral vitamin B₁₂ to patients suspected of cyanocobalamin hypersensitivity prior to starting NASCOBAL[®].

INDICATIONS

- Treatment of adult patients with dietary, drug-induced, or malabsorption-related vitamin B₁₂ deficiency not due to pernicious anemia
- Prevention of vitamin B_{12} deficiency in adult patients with vitamin B_{12} requirements in excess of normal

Please see additional Important Safety Information throughout. Please see the full Prescribing Information available from representative.

WILLIAM, 48 YEARS OLD		
Divorced, with 2 children	BMI: 33 (obese)	
Marketing Director	BP: 148/90	
6 ft 0 in, 243 lb	Commercial insu	
MEDICATIONS		

etes 6 years ago	Metformin	Pantoprazole
	Atorvastatin	Beta-blocker
	Hydrochlorothiazide	
sease (GERD)		

• Vitamin B₁₂ maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin B₁₂ therapy and who have no nervous system involvement



surance




RATIONALE FOR TESTING AND TREATING VITAMIN B₁₂ DEFICIENCY IN DIABETICS TAKING METFORMIN

Vitamin B₁₂ deficiency is a potential comorbidity of Type 2 diabetes.¹ Despite its ability to effectively lower blood glucose in patients with Type 2 diabetes, metformin has been documented to decrease vitamin B₁₂ levels. Risk of metformin-associated vitamin B₁₂ deficiency in patients with Type 2 diabetes increases with increasing age, higher metformin dose, and longer duration of use.²

Reports indicate that 30% of patients receiving long-term metformin treatment experience malabsorption of vitamin B₁₂, with reductions in serum vitamin B₁₂ concentration of 14% to 30%.³ Sensory polyneuropathy could be a symptom of vitamin B₁₂ deficiency that closely mimics diabetic neuropathy. This underscores the need to check vitamin B₁₂ levels and screen these

Sensory polyneuropathy could be a symptom of vitamin B_{12} deficiency patients for vitamin B_{12} deficiency.²



IMPORTANT SAFETY INFORMATION FOR NASCOBAL® NASAL SPRAY (cont)

Patients with Leber's disease who were treated with vitamin B₁₂ suffered severe and swift optic atrophy. NASCOBAL® is not recommended for use in patients with Leber's optic atrophy.

Doses of vitamin B₁₂ exceeding 10 mcg daily may produce hematologic response in patients with folate-deficient megaloblastic anemia, and may therefore mask a previously unrecognized folate deficiency. NASCOBAL[®] is not a substitute for folic acid. Assess both vitamin B₁₂ and folate levels prior to initiating therapy with NASCOBAL[®].

Hypokalemia, thrombocytosis and sudden death may occur in severe megaloblastic anemia which is treated intensely with vitamin B₁₂. Serum potassium levels and platelet count should be monitored.

Please see additional Important Safety Information throughout. Please see the full Prescribing Information available from representative.

SPECIMEN: SERUM (HYPOTHETICAL)

	Patient's Results	Ref. Range	Units
	L190	200-10004	pg/mL
	L320	340-10204	ng/mL
	H0.425	>0.3764*	µmol/L
	H13.7	>13.24*	µmol/L
al Ro	ange L = Abnormal La	w H = Abnormal High	

NASCOBAL[®] may be considered as a vitamin B₁₂ supplement in circumstances where a prescriber has determined that metformin should be continued in a diabetic patient where vitamin B₁₂ deficiency persists.

s with Leber's optic atrophy. mask a previously unrecognized folate




THE ONLY FDA-APPROVED PRESCRIPTION VITAMIN B_{12} NASAL SPRAY⁵

CLINICALLY PROVEN TO HAVE INCREASED VITAMIN B12 LEVELS FROM THE FIRST DOSE⁶

- Achieved mean peak serum vitamin B_{12} concentration within 1.5 hours⁶*
- Reached mean peak concentration of 1,021 pg/mL^{6*}
- \blacktriangleright At 72 hours, mean serum vitamin B₁₂ level was increased by 46% above baseline^{6*}

*In 21 healthy volunteers under fasting conditions, a single 500-mcg dose of NASCOBAL® was given and monitored for 3 days. Data are based on baseline-uncorrected serum vitamin B₁₂ levels.⁶

INTRANASAL ADMINISTRATION HAS MAINTAINED HEALTHY VITAMIN B_{12} LEVELS



IMPORTANT SAFETY INFORMATION FOR NASCOBAL® NASAL SPRAY (cont)

Treatment with vitamin B₁₂ may unmask signs of polycythemia vera. Patients exhibiting clinical or hematologic response consistent with polycythemia vera should be referred for further evaluation.

Hematocrit, reticulocyte count, vitamin B₁₂, folate and iron levels should be obtained prior to treatment. Consider the potential for concomitant drugs to interfere with vitamin B₁₂ and folate diagnostic blood assays. Vitamin B₁₂ and peripheral blood counts must be monitored initially at one month after the start of treatment, and then at intervals of 3 to 6 months. If a patient is not properly maintained with NASCOBAL[®], consider alternative therapy.

Please see additional Important Safety Information throughout. Please see the full Prescribing Information available from representative.

Once-a-week Intranasal Dosing maintained higher serum vitamin B₁₂ levels than 1 intramuscular vitamin B_{12} injection after 28 days In 24 patients with a history of pernicious anemia, a single-dose cyanocobalamin 100-mcg/mL IM injection was given and monitored for 28 days, followed by 4 once-weekly doses of intranasal (IN) vitamin B_{12} gel 500 mcg/0.1 mL. Mean baseline serum vitamin B₁₂ prior to IN dosing = 351.4 pg/mL, and at day 28 = 480.7 pg/mL.⁷ In a separate study, bioavailability of vitamin B_{12} nasal spray was 10% less than vitamin B₁₂ nasal gel. Clinical significance is unknown.⁸





CONVENIENT, ONCE-WEEKLY DOSING REGIMEN

SELF-ADMINISTERED: 1 SPRAY, 1 NOSTRIL, 1x A WEEK⁸

Dose adjustments may be required.

AN AFFORDABLE TREATMENT FOR VITAMIN B₁₂ DEFICIENCY

ELIGIBLE PATIENTS MAY GET NASCOBAL® FOR AS LITTLE AS \$0 PER MONTH*

Download Copay Cards at Nascobal.com.

*Patients may redeem this offer ONLY when accompanied by a valid prescription. Offer is valid up to a maximum benefit of \$150. Offer is not valid for patients whose prescriptions are reimbursed in whole or in part under Medicaid, Medicare, Medigap, VA, DoD, TRICARE, or any other federal or state programs (such as medical assistance programs) or where otherwise prohibited by law. Offer is not valid in VT or where prohibited in whole or in part. This offer may be amended or ended at any time without notice.

IMPORTANT SAFETY INFORMATION FOR NASCOBAL® NASAL SPRAY (cont)

If NASCOBAL[®] is used concomitantly with chloramphenicol, monitor for reduced efficacy and, if needed, consider an alternative therapy. The limited available data on NASCOBAL® in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. The most common adverse reactions ($\geq 4\%$) were infection, headache, glossitis, paresthesia, asthenia, nausea and rhinitis.

Please see additional Important Safety Information throughout. Please see the full Prescribing Information available from representative.

NASCOBAL® Nasal Spray should be administered at least one hour before or one hour after ingestion of hot foods or liquids.





IMPORTANT SAFETY INFORMATION

INDICATIONS

- Treatment of adult patients with dietary, drug-induced, or malabsorption-related vitamin B₁₂ deficiency not due to pernicious anemia
- Prevention of vitamin B_{12} deficiency in adult patients with vitamin B_{12} requirements in excess of normal

Limitations of Use

- NASCOBAL[®] should not be used for the vitamin B_{12} absorption test (Schilling test).
- and underlying disease has not been established.
- NASCOBAL[®] should be deferred until symptoms have subsided.

IMPORTANT SAFETY INFORMATION FOR NASCOBAL® NASAL SPRAY

NASCOBAL[®] is contraindicated in patients with sensitivity to cobalt, vitamin B₁₂, or any component of the medication. Anaphylactic shock and death have been reported with parenteral forms of vitamin B₁₂. Consider administering an intradermal test dose of parenteral vitamin B₁₂ to patients suspected of cyanocobalamin hypersensitivity prior to starting NASCOBAL[®]. Patients with Leber's disease who were treated with vitamin B₁₂ suffered severe and swift optic atrophy. NASCOBAL[®] is not recommended for use in patients with Leber's optic atrophy. Doses of vitamin B₁₂ exceeding 10 mcg daily may produce hematologic response in patients with folate-deficient megaloblastic anemia, and may therefore mask a previously unrecognized folate deficiency. NASCOBAL[®] is not a substitute for folic acid. Assess both vitamin B₁₂ and folate levels prior to initiating therapy with NASCOBAL[®]. Hypokalemia, thrombocytosis and sudden death may occur in severe megaloblastic anemia which is treated intensely with vitamin B₁₂. Serum potassium levels and platelet count should be monitored.

Treatment with vitamin B₁₂ may unmask signs of polycythemia vera. Patients exhibiting clinical or hematologic response consistent with polycythemia vera should be referred for further evaluation.

Hematocrit, reticulocyte count, vitamin B₁₂, folate and iron levels should be obtained prior to treatment. Consider the potential for concomitant drugs to interfere with vitamin B₁₂ and folate diagnostic blood assays. Vitamin B₁₂ and peripheral blood counts must be monitored initially at one month after the start of treatment, and then at intervals of 3 to 6 months. If a patient is not properly maintained with NASCOBAL[®], consider alternative therapy. If NASCOBAL[®] is used concomitantly with chloramphenicol, monitor for reduced efficacy and, if needed, consider an alternative therapy. The limited available data on NASCOBAL® in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. The most common adverse reactions ($\geq 4\%$) were infection, headache, glossitis, paresthesia, asthenia, nausea and rhinitis.

Please see the full Prescribing Information available from representative.

References: 1. Pflipsen M, Oh R, Saguil A, et al. The prevalence of vitamin B12 deficiency in patients with type 2 diabetes: A cross-sectional study. J Am Board Fam Med. 2009;22:528–534. 2. Kibirige D, Mwebaze R. Vitamin B12 deficiency among patients with diabetes mellitus: is routine screening and supplementation justified? J Diabetes Metab Disord. 2013;12(1):17. 3. Liu Q, Li S, Quan H, Li J. Vitamin B12 status in metformin treated patients: systematic review. PLoS ONE. 2014;9(6):e100379. 4. Parrott J, Frank L, Rabena R, et al. American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update: Micronutrients. Surg Obes Relat Dis. 2017:1-15. 5. US Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations. 41st ed. https://www.fda.gov/media/71474/download. Accessed January 28, 2021. 6. Data on File. DOF-NS-02. Endo Pharmaceuticals Inc.; 2016. 7. Data on File. DOF-NS-01. Endo Pharmaceuticals Inc.; 2015. 8. NASCOBAL® [Prescribing Information]. Chestnut Ridge, NY: Par Pharmaceutical Companies.

• Vitamin B₁₂ maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin B₁₂ therapy and who have no nervous system involvement

• In patients with correctible or temporary causes of vitamin B₁₂ deficiency, the benefit of continued long-term use of NASCOBAL® following adequate correction of vitamin B₁₂ deficiency

• The effectiveness of NASCOBAL® in patients with active symptoms of nasal congestion, allergic rhinitis or upper respiratory infection has not been determined. Treatment with



